Completed PHASE2 INTERVENTIONAL NCT00042679

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Sponsor: Eli Lilly and Company

Conditions Carcinoma, Non-Small-Cell Lung Neoplasms, Lung Pulmonary Neoplasms

Interventions Carboplatin Gemcitabine LY900003

Updated 5 times since 2017 Last updated: Jul 18, 2006 Started: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Carcinoma, Non-Small-Cell Lung and Neoplasms, Lung, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States , Baltimore, United States , Berkeley, United States , Charlottesville, United States , Chattanooga, United States , Chicago, United States , Lubbock, United States , Miami Beach, United States , Milwaukee, United States , Park Ridge, United States and 1 more location